5'- O- (9- phenylxanthen- 9- yl)- 2'- deoxynebularine

01/01/2019 - "These findings point to EPX and PXDN as potential therapeutic targets for renal fibrosis and CKD and suggest that eosinophils modulate the response to renal injury."
01/01/2022 - "Mouse models of liver fibrosis and cirrhosis patients were analyzed for the expression of PXDN in liver and serum. "
12/01/2021 - "Although PXDN has been linked to fibrosis and cancer in some organs there is limited information on its role in development, including in the breast. "
10/20/2018 - "Aberrant PXDN expression has been associated with kidney fibrosis, cancer, congenital eye defects and various cardiovascular disorders. "
01/01/2019 - "Our study defines the contribution of MPO, EPX, and PXDN to renal inflammation and tubulointerstitial fibrosis in the murine unilateral ureteral obstruction (UUO) model. "

10/08/2022 - "Alpha-ketoglutarate ameliorates abdominal aortic aneurysm via inhibiting PXDN/HOCL/ERK signaling pathways."

11/01/2014 - "Our studies provide pathogenic mechanisms of PXDN mutation-induced congenital eye diseases. "
06/01/2016 - "An examination of the regulatory mechanism of Pxdn mutation-induced eye disorders using microarray analysis."
06/01/2016 - "The present study aimed to identify biomarkers for peroxidasin (Pxdn) mutation-induced eye disorders and study the underlying mechanisms involved in this process. "
12/05/2019 - "PXDN mutations lead to severe eye disorders, including microphthalmia, cataract, glaucoma, and anterior segment dysgenesis in humans and mice. "
11/01/2014 - "Mutations in Peroxidasin (PXDN) cause severe inherited eye disorders in humans, such as congenital cataract, corneal opacity and developmental glaucoma. "

01/01/2022 - "This study employed data from multiple databases, including The Cancer Genome Atlas and The Genotype-Tissue Expression, to conduct a specific pan-cancer analysis of the effects of PXDN expression on cancer prognosis. "
01/01/2022 - "However, the role and specific mechanism of PXDN in tumor are unclear, and no systematic pan-cancer studies on PXDN have been reported to date. "
01/01/2022 - "The results of tissue microarray immunohistochemistry showed that the expression of PXDN was significantly correlated with tumor size and pathological grade. "
01/01/2022 - "Additionally, for the first time, the relationship of PXDN with the tumor microenvironment and infiltration of fibroblasts and different immune cells within different tumors was explored, and the possible molecular mechanism of the effect was also discussed. "
01/01/2022 - "A systematic pan-cancer analysis of PXDN as a potential target for clinical diagnosis and treatment."

10/20/2023 - "In addition to patient serum, we analyzed primary melanoma tumor cells from NR and found a potential marker signature with 4 key markers: LAMC1, PXDN, SERPINE1, and VCAN."
02/22/2022 - "According to our analysis, 66% of the isoforms presented differential expression on melanoma progression: NOS2, SOD1, NOX4, PRX3, PXDN and GPX1 are increased during melanoma progression, while CAT, GPX3, TXNIP, and PRX2 are decreased. "
07/05/2016 - "Furthermore, migration of PXDN, NTN4 or GLIS3 siRNA transfected melanoma cells was inhibited following transplantation into the embryonic chicken neural tube compared to control siRNA transfected melanoma cells. "
07/05/2016 - "Our study suggests that PXDN, NTN4 and GLIS3 play a functional role in promoting melanoma cellular invasion, and therapeutic approaches directed toward inhibiting the action of these proteins may reduce the incidence or progression of metastasis in melanoma patients."
07/05/2016 - "We identified Peroxidasin (PXDN), Netrin 4 (NTN4) and GLIS Family Zinc Finger 3 (GLIS3) genes consistently elevated in invasive mesenchymal-like melanoma cells. "